This may account for some of the effectiveness of HDAC inhibitors as cancer therapeutics [30], and we found cell lines that were sensitive to knockdown of MYC or ATAD2 were also sensitive to the HDAC inhibitor Trichostatin-A. The gene discussed is MYC; the disease is cancer.